According to this sequential mechanism, programmed death-ligand 1 or programmed cell death protein 1 inhibitors that impede immune tolerance between cytotoxic T lymphocytes and cancer cells may synergistically function with the blockade of the CCL2–CCR2 axis as a combination anticancer treatment. The gene discussed is CCR2; the disease is cancer.